AnodyneWiki

Psilocybin

4-PO-DMT
Psilocybin
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass284.25 g/mol [1]
AppearanceCrystals from boiling water [1]
TasteSlightly ammonia-like [1]
Melting point220-228 °C [1]
SolubilitySoluble in 120 parts boiling methanol; difficultly soluble in ethanol; practically insoluble in chloroform, benzene. [1]
Predicted LogP-1.6 [1]
Structural Identifiers
[]
Molecular formulaC12H17N2O4P
IUPAC name[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
SMILESCN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O
InChIInChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N
CAS number520-52-5
UNII2RV7212BP0
PubChem CID10624
Pharmacokinetics[]
OnsetOral: 0.5–0.8 (range 0.1–1.5) h, Intravenous injection: immediate
Elimination half-lifeOral (as psilocin): 2.1–4.7 h (range 1.2–18.6 h), Intravenous administration (as psilocin): 1.2 h (range 1.8–4.5 h)
Duration of actionOral: 4–6 h (range 3–12 h), Intravenous injection: 15–60 min (1–2 mg)[3]
MetabolismLiver, other tissues:, • Dephosphorylation (alkaline phosphatase), • Demethylation and deamination (monoamine oxidase), • Oxidation (aldehyde dehydrogenase), • Glucuronidation (UDP-glucuronyltransferases)[4][5]
Excretionurine (mainly as psilocin-O-glucuronide, 2–4% as unchanged psilocin)
Routes of administrationBy mouth,, intravenous
Dependence liabilityLow[6]
Addiction liabilityLow
Toxicity
[]
Mouse:
- iv: 285 mg/kg
Rabbit:
- iv: 12.5 mg/kg
Rat:
- iv: 280 mg/kg
- Oral: 280 mg/kg
 [1]

Psilocybin (also known as Psilocybine, Indocybin, Psilocibin, Teonanacatl, Psilocin phosphate ester, Psilocibina, Psilotsibin, Psilocybinum, Cy-39 or O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a psychedelic substance of the tryptamine class.

It is a constituent of psilocybe cubensis.

Chemistry

 []

Psilocybin is achiral.

Psilocybin matches Lipinski's rule of five.

There are currently 4 reagent-interactions on

ReagentColor changeDescription
Marquisorange
Meckeyellow green > brownish
Ehrlichpurple
Hofmannyellow / green

Pharmacology

Mechanism of action []

Psilocybin, which resembles 5-hydroxytryptamine and LSD, inhibits the firing of serotonin-dependent neurons, causing alterations in perception, changes in mood, hallucinations, and a distortion of time. [1]

Subjective effects []

emily / Psilocybin []
Routes:
  • Oral (6 - 12mg)
magnus / Psilocybin []
Routes:
  • Oral
Effects:Notes:
  • via magic mushrooms and magic truffels; slightly more calm headspace than LSD and its analogues; brighter visuals which have a more futuristic feel to them like 2C-B

Experience reports

Erowid

There are currently 13 experience reports involving psilocybin on : []

Reddit

There are currently 50 trip reports involving psilocybin on : []

 []

  • Australia: Psilocybin is a S9/S8 (Controlled Drug).
  • Brazil: Psilocybin is a F2.[7]
  • Canada: Psilocybin is a Schedule III.
  • United Kingdom: Psilocybin is a Class A under the "Misuse of Drugs Act 1971".
  • United States: Psilocybin is a Schedule I under the "Controlled Substances Act".

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 10624, Psilocybin. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/10624
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Psilocybin. UNII: 2RV7212BP0. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2RV7212BP0
  3. Yerubandi A, Thomas JE, Bhuiya NM, Harrington C, Villa Zapata L, Caballero J. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Network Open. April 2024; 7(4). PMID 38598236. https://doi.org/10.1001/jamanetworkopen.2024.5960
  4. Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. The Therapeutic Potential of Psilocybin. Molecules. May 2021; 26(10):2948. PMID 34063505. https://doi.org/10.3390/molecules26102948
  5. Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. Journal of Xenobiotics. February 2022; 12(1):41–52. PMID 35225956. https://doi.org/10.3390/jox12010004
  6. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. November 2018; 142():143–166. PMID 29753748. https://doi.org/10.1016/j.neuropharm.2018.05.012
  7. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. July 24, 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 08:21:45
drugsprook2026-11-20 08:21:41
erowidok2026-11-20 08:21:43
gsrsok2026-11-20 08:21:41
hmdbmissing (hmdb.ca refused automated access to HMDB0256899)2026-11-20 08:21:41
keggok2026-11-20 08:21:42
pubchemok2026-11-20 08:21:40
redditok2026-11-20 08:21:41
sidermissing (not in SIDER)2026-11-20 08:21:41
structureok2026-11-20 08:21:41
wikipediaok2026-11-20 08:21:41